Biostar Stock Soars (BSPM)

NEW YORK ( TheStreet) -- Shares of Biostar Pharmaceuticals (Nasdaq: BSPM) have taken a tremendous swing upward. The stock is trading at $2.05 as of 10:05 a.m. ET, 24.2% above Friday's closing price of $1.65. Volume is at 135,147, 1.9 times the daily average of 72,400.

Biostar has a market cap of $17.4 million and is part of the health care sector and drugs industry. Shares are up 165.4% year to date as of the close of trading on Friday.

Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products, and health supplement products for various diseases and conditions in the People's Republic of China. The company has a P/E ratio of 1.2, below the average drugs industry P/E ratio of 1.4 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Biostar as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. You can view the full Biostar Ratings Report.

See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center.

null

More from Markets

Dow's Losses Accelerate After U.K.'s May Delays Brexit Vote

Dow's Losses Accelerate After U.K.'s May Delays Brexit Vote

Apple Has Been the Market's Biggest Sore Point Lately

Apple Has Been the Market's Biggest Sore Point Lately

Legal Quarrel With Qualcomm Adds to Apple Shareholder Anxiety Over China

Legal Quarrel With Qualcomm Adds to Apple Shareholder Anxiety Over China

Appetite for Fixed Income Is Rising, and This Chart Shows Us Why

Appetite for Fixed Income Is Rising, and This Chart Shows Us Why

Nutrisystem Soars on Deal to Be Acquired by Tivity Health

Nutrisystem Soars on Deal to Be Acquired by Tivity Health